Because alectinib has shown favorable survival benefit with acceptable toxicities in the first-line setting, the antitumor activity of other ALK-TKIs following first-line alectinib has been investigated in ALK-positive NSCLC patients with resistance to alectinib. This evidence concerns the gene ALK and non-small cell lung carcinoma.